Background In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy.
Introduction
Neonatal encephalopathy affects 2-8 in every 1000 livebirths and carries a high risk of death or severe disability. 1 Thera peutic hypothermia has been shown to reduce this risk but many treated infants still go on to develop substantial lifelong disabilities. 2 In neuroprotective trials that target neonatal encephalo pathy, there is a crucial difficulty in the assessment of treatment efficacy: an accurate clinical measurement of neurodevelopment can only be taken after a delay of sev eral years. Currently, more than a dozen putative neuro protectants are awaiting clinical evaluation on the evi dence of promising preclinical work. 3 Thalamic proton magnetic resonance (MR) spectroscopy (MRS), obtained within days or weeks of the initial injury, gives insight into the metabolic effects of neonatal encephalopathy and hence could be useful in quantifying treatment effects of neuroprotective therapies. [4] [5] [6] Although metaanalyses have shown that proton MRS provides accurate prognosis in neonatal encephalopathy across various singlecentre studies, 7, 8 it is challenging to achieve similar results across a network of institutions with different MR scanners. 9 No such studies have been done in pragmatic multicentre clinical settings, as is required for large neuroprotection trials. Because each MR scanner is supplied with its own proprietary software for clinical use, each having its own hardware and software configuration, substantial work is required to ensure any quantitative results are comparable across institutions. Thus, despite the promise and wide avail ability of proton MRS on all modern scanners, it has not yet entered mainstream use in clinical practice.
The expert MRS Consensus Group has highlighted several key pathologies where proton MRS can have a substantial impact on the clinical management of pa tients, including neonatal encephalopathy, but con cludes that important barriers need to be overcome to achieve this routinely. 10 Particularly, they highlight the need for prospective multicentre clinical trials with robust stand ardisation, analysis, and quality assurance. In this study, our aim was to harmonise the acquisition of robust thalamic proton MRS biomarkers across several tertiary neonatal care centres and assess their accuracy in pre dicting adverse neurodevelopment in term or nearterm infants 2 years after neonatal encephalopathy.
Methods

Study design and participants
The magnetic resonance biomarkers in neonatal en cephalopathy (MARBLE) study recruited consecutive term and nearterm infants (36-43 weeks' gestation) with neonatal encephalopathy who received therapeutic hypo thermia, with staggered start dates across eight partici pating neonatal intensive care units in the UK and USA. Infants were excluded if they had lifethreatening con genital malformations, syndromic disorders, or neuro metabolic diseases. The study was approved by the North London Research Ethics Committee (13HH1843), and each of the participating clinical sites. All parents provided written informed consent, as stipulated by the ethics committee. 11 The study protocol is available online.
Procedures
Upon recruitment at each site, infants were assessed according to the National Institute of Child Health and Human Development (NICHD) neurological examination with an additional categorisation for mild encephalo
Research in context
Evidence before this study We searched MEDLINE (PubMed interface) and Embase without any language restrictions for articles published from Jan 1, 1990 , to May 1, 2018, using Medical Subject Heading terms and the following keywords: [magnetic resonance imaging OR magnetic resonance spectroscopy] AND [hypoxic ischemic encephalopathy] AND [newborn OR neurodevelopmental outcome]. We also examined the references and bibliographies from retrieved articles. 42 single-centre prospective or retrospective studies (the largest prospective study including 33 infants) compared proton magnetic resonance (MR) spectroscopy (MRS) metabolite peak-area ratios in infants with neonatal encephalopathy with neurodevelopmental outcome at 12 months or older, of which four also examined absolute metabolite concentrations. Four retrospective studies compared the proton MRS in encephalopathic infants who had therapeutic hypothermia with later neurodevelopmental outcomes, of which only two used 3·0 Tesla MR scanners. Although all the studies reported that proton MRS was a good predictor of neurodevelopmental outcome, the MR acquisition details, voxel positioning, scanner types, and prognostic cutoff thresholds varied widely. The lack of generalisability in these studies therefore resulted in minimal clinical impact.
We found no published data of proton MRS studies using different MR scanner models across different vendors, with harmonised acquisitions. Three recent systematic reviews of the published literature on MRS in neonatal encephalopathy, and a consensus group of MRS experts, concluded that the absence of such multicentre proton MRS studies is the biggest roadblock preventing the mainstream clinical application of MRS.
Added value of this study
To our knowledge, this is the first large prospective and pragmatic multicentre study assessing the prognostic accuracy of proton MRS in neonatal encephalopathy. This investigation involved clinical 3·0 Tesla MR systems from three prominent vendors, to ensure widespread applicability to pragmatic clinical settings. In this context, we showed that the thalamic concentration of N-acetylaspartate (NAA), measured within 14 days after birth, accurately predicted adverse neurodevelopmental outcomes 2 years later. Proton MRS biomarkers, independent of any other measures, gave a substantial improvement in prognostic accuracy over available clinical measures and conventional MRI scoring.
Implications of all the available evidence
Proton MRS should be a routine component of clinical MR protocols for infants with neonatal encephalopathy. This assessment is ideal for early prognostication and might provide promising surrogate outcome measures for multicentre clinical trials. If early-phase trials were to employ proton MRS measures such as NAA concentration, this would greatly increase their power to detect important treatment effects while potentially reducing their duration by several years.
For the study protocol see https://www.imperial.ac.uk/ perinatal-neuroscience/currentresearch/neuroprotectivetherapies pathy. 12 This yielded an encephalopathy grade (none, mild, moderate, or severe) which reflected the severity of neurological symptoms across six categories (appendix). For the study, we did MR brain scans 4-14 days after birth on a 3.0 Tesla scanner (Philips [Amsterdam, Netherlands], Siemens [Munich, Germany], or GE Healthcare [Chicago, IL, USA]), with harmonised proto cols. 11 The MR protocol (acquisition time) com prised T 1 weighted and T 2 weighted MRI (15 min) and diffusionweighted MRI (DWMRI; 7 min), proton MRS metabolite peakarea ratios (7 min), and proton MRS metabolite absolute concentrations (25 min). We did MRS in a single 15 × 15 × 15 mm³ voxel centred on the left thalamus (appendix). Pseudonymised MR data were transferred to Imperial College London (London, UK) for postprocessing and analysis. An MR physicist (PJL) analysed the MRS and DWMRI data, and a neo natal neurologist (ST) with 10 years of MR experience reported the conventional MRI data using a validated scoring system 13 while masked to the clinical outcomes (appendix).
We classified the amplitude integrated EEG (aEEG) background activity as normal (upper margin of aEEG activity band >10 μV and lower margin >5 μV); moderately abnormal amplitude (upper margin >10 μV and lower margin <5 μV); or severely abnormal amplitude (upper margin <10 μV and lower margin <5 μV). 14 We assessed neurodevelopmental outcome using the Bayley Scales of Infant and Toddler Development, third edition (BayleyIII) cognitive, language, and motor composite scores and a detailed neurological exam ination by trained and certified examiners who were masked to the MRS and DWMRI data. We defined severe disability as any of the following: BayleyIII composite cognitive and language scores less than 70, Gross Motor Function Classification System (GMFCS) levels 3-5, hearing impairment requiring hearing aids, or blindness. We defined moderate disability as composite cognitive and language scores between 70 and 84, and any of the following: GMFCS level 2, hearing impairment without the need for amplification, or a persistent seizure disorder. 
Outcomes
The primary objective was to examine the accuracy of quantitative cerebral MR biomarkers for predicting adverse 18-24month neurodevelopmental outcome, as measured by a composite of death or moderate or severe disability in survivors after therapeutic hypothermia for neonatal encephalopathy.
Secondary outcomes (which are not reported here) were intercentre variability of proton MRS measurements and the incremental benefits of quantitative MR bio markers for predicting adverse outcomes when compared with conventional MRI assessment and bedside assessments and investigations.
We selected the following key MR biomarkers of interest: thalamic concentration of Nacetylaspartate (NAA); peak area ratios of thalamic lactate to NAA, NAA to creatine, and NAA to choline; basal ganglia or thalamic injury or cortical injury on T 1 weighted and T 2 weighted MRI; loss of the normal high signal intensity of the posterior limb of internal capsule (PLIC) on T 1 weighted MRI; and fractional anisotropy in the PLIC (from DWMRI); in addition to a structured clinical neurological examination and moderate or severe voltage abnormality of aEEG within the first 6 h of age and at discharge. We considered all these markers for inclusion in a single multivariable prognostic model in predicting an adverse outcome at 2 years.
Statistical analysis
We calculated the sample size using the socalled rule of ten generally used to calculate the sample size require ments for developing prognostic models. The multivariable risk model required a total sample size of 180, assuming an adverse outcome in 50% of participants. We increased the sample size to 220 to account for attrition and poor data quality. Comparisons of continuous biomarkers between infants with normal and adverse outcomes were done using the unpaired t test if the variables were normally distributed or the MannWhitney test if they were not.
We also used receiver operating characteristic (ROC) curves to examine the prognostic accuracy of these bio markers and obtained prognostic indices with 95% CIs using the exact binomial method.
Finally, we used linear regression to examine the association between the nine key biomarkers and the cognitive, language, and motor composite scores obtained with BayleyIII. Where infants had severe disability, irrespective of encephalopathy grade, that prevented them from undertaking BayleyIII, we assigned nominal values for the composite scores in each domain (cognitive=54, language=46, motor=46). We examined the association between each biomarker and BayleyIII scores in separate linear regression analyses, followed by a multivariable analysis to examine the joint association. We employed a backwards selection procedure to retain only statistically significant factors in the final models. Due to its skewed distribution, we analysed the peakarea ratio of lactate to NAA on the log scale. We adjusted all regression analyses for birth gestational age and postnatal age at MRI.
This trial is registered with ClinicalTrials.gov, number NCT01309711.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or 1 ). Of the infants with outcome data, 31 (16%) had an adverse neurodevelopmental outcome (death or moderate or severe disability). The clinical characteristics, brain injury, and neurodevelopmental outcomes of infants who had thalamic NAA concentration measurements were similar to those who did not (appendix). Across all eligible infants, the mean birthweight was 3·4 kg (SD 0·6), at a mean gestational age of 39·9 weeks (1·5), with 216 infants undergoing 72 h of moderate hypothermia (33·5°C), six infants being re warmed prior to 72 h, and one infant being rewarmed after 96 h due to local clinical decisions (table 1) . According to assessment against NICHD criteria within the first 6 h after birth, encephalopathy was graded severe in 23 (10%) infants, moderate in 163 (73%), and mild in 36 (16%). In one more case, the infant was initially assessed as having no encephalopathy at admission but this progressed within the first 6 h to mild neonatal encephalopathy and a clinical decision was made to begin hypothermia (table 2). MR scanning was done at a mean age of 8·4 days (SD 4·3), which did not differ between infants who went on to have normal or adverse outcomes (p>0·5; MannWhitney U).
The prognostic accuracy of the biomarkers in predicting an adverse outcome is shown in figure 2 , with ROC curves of the most commonly used biomarkers shown in the appendix. Clinical neurological examination at discharge had a good specificity but poor sensitivity (figure 2). This had poorer prognostic accuracy than the equivalent neurological examination done within 6 h of birth, with a sensitivity of 42% (95% CI 25-61) and specificity of 94% (89-97). aEEG done within the first 6 h of birth had a similar sensitivity and specificity to the neurological examination done within 6 h of birth (figure 2).
From T 1 weighted and T 2 weighted MRI, the most predictive measure was any evidence of injury to either the PLIC or the basal ganglia or thalamus (figure 2).
Thalamic NAA concentration was the single best prognostic indicator, with an area under the curve (AUC) of 0·99 (95% CI 0·94-1·00) and high sensitivity and 2) . The mean NAA concentration in infants with normal outcomes was 7·1 mmol/kg wet weight (SD 0·8) and 4·0 mmol/kg wet weight (1·3) in those with adverse outcomes (p<0·0001; t test). Although NAA concentration increased with gestational age at birth (Pearson correlation coefficient r = 0·31; p=0·0031), there was no relation with postnatal age (r = 0·02; p=0·83).
Neither gestational age nor postnatal age at the MR scan were associated with adverse outcomes (appendix). The lactate-NAA peakarea ratio had an AUC of 0·94 (0·89-0·97; figure 2 ). The median lactate-NAA peak area ratio was 0·14 (IQR 0·11-0·18) in infants with a nor mal outcome and 0·43 (0·25-0·79) in infants with an ad verse outcome (p<0·0001; MannWhitney U). Mean 
Area under the ROC curve NAA-creatine peakarea ratios in infants with normal and adverse outcomes was 1·56 (SD 0·23) in infants with normal outcomes and 1·25 (0·31) in those with adverse outcomes whereas mean NAA-choline peakarea ratios were 0·84 (0·15) in infants with normal outcomes and 0·71 (0·13) in those with adverse outcomes (p<0·0001 for both analyses; t test). Figure 3 shows the thalamic metabolite distributions and outcomes. NAA concentra tion was normally distributed and showed a clear separa tion between infants with normal and adverse outcomes. By contrast, the lactate-NAA ratio showed a highly skewed distribution with clustering around a narrow range. From DWMRI, the fractional anisotropy in the PLICs had an AUC of 0·92 (95% CI 0·76-1·00). The group median fractional anisotropy in the PLICs of infants with adverse outcomes was significantly lower than for those with normal outcomes (0·34 [IQR 0·33-0·38] vs 0·46 [0·44-0·49]; p=0·0054; MannWhitney U; figure 4 ). Using a groupwise tractbased spatial statistics analysis, and controlling for gestational age at scan, infants who had an adverse neurodevelopmental outcome had lower fractional anisotropy throughout their cerebral white matter ( figure 4) .
Thalamic NAA concentration alone accurately pre dicted an adverse outcome, and so multiple logistic regression analysis could not be done because the models would not converge when any additional variable was examined, suggesting the metabolic peakarea ratios were not independently associated with adverse out comes. It is unlikely a second variable would have been able to improve diagnostic performance.
Our final set of analyses examined the relationship between each of the MR measures with the continuous neurodevelopmental outcome scores from BayleyIII. When we examined them individually, all nine were significantly associated with these scores (all p<0·0001). Multivariable analyses, summarised in the appendix, suggested that only NAA concentration and PLIC scoring were independently associated with all three outcomes. We found a nonlinear relationship between NAA con centration and each of the scores. We observed a positive association between scores and NAA concen tration, although this relation tailed off for high values of NAA concentration ( figure 5 ).
Discussion
To our knowledge, MARBLE was the largest prospective prognostic study of proton MRS in neonatal encephalo pathy, collecting carefully standardised results across multiple sites that reflect the range of MR scanners in clinical use, and employing rigorous quality assurance and centralised analysis. The results provide evidence of the high accuracy of thalamic proton MRS, acquired days after birth, in predicting adverse neuro develop ment 2 years after neonatal encephalopathy. Thalamic NAA concen tration had the highest accuracy in predict ing neuro developmental outcome following neonatal en cepha lopathy (AUC 0·99, 95% CI 0·94-1·00) and was associated with performance across cognitive, lang uage, and motor domains at 2 years of age. Given this high prognostic accuracy, it was not possible to dev elop a multivariable prediction model including other parameters.
Although the lactate-NAA peakarea ratio had a sensitivity of 88% (95% CI 70-98) and specificity of 90% (84-95), confirming the results of our previous meta analysis, 7 this was overshadowed by the strength of the association between NAA concentration and adverse outcome, which suggests that the lactate-NAA peakarea ratio was not independently associated with adverse outcomes. Thus, the prognostic accuracy of the lactate-NAA peakarea ratio appears to be primarily driven by NAA concentration. Furthermore, unlike NAA con centration, the metabolic information obtained from the lactate-NAA peakarea ratio is ambiguous. Not only is it affected by changes in metabolite concentrations but also their relaxation characteristics and acquisitiondependent chemical shift artifacts. Finally, the diverging time courses of lactate and NAA concentration, the skewed distribution of the lactate-NAA peakarea ratio, and the uncertain effect of cooling therapy on lactate concentration [15] [16] [17] [18] limits use of the lactate-NAA peakarea ratio as a surrogate endpoint in multicentre trials. However, given the high prognostic accuracy and short acquisition times in routine clinical settings, this ratio would add substantial value to standard clinical imag ing protocols. Although NAA concentration increased with gestational age, postnatal age did not influence concentration in infants with neonatal encephalopathy. Hence, the MR scanning could be acquired any time within the first 14 days after birth without affecting the prognostic accuracy. Clinical examination at birth alone could not accurately identify infants at risk of adverse neurodevelopment, and we found that a second examination at discharge was even less effective. aEEG within 6 h of birth did not enhance the prognostic accuracy of the structured clinical exam ination, confirming data from a previous metaanalysis 19 and from cooling trials. 12 Following hypothermia, con ventional MRI is most frequently used in prognostica tion in clinical settings but its interpretation is subjective and scoring systems are only semiquantitative. In the present study, basal ganglia or thalamic injury on con ventional MRI had a sensitivity of 71% (95% CI 52-86) and specificity of 88% (82-93). These results agreed with our previous metaanalysis 7 of data obtained at a time when moderate hypothermia was still the subject of various randomised controlled trials but had not yet been implemented in widespread clinical practice. Three substudies of large cooling trials (TOBY 13 with 64 participants, NICHD 20 with 73, and ICE 21 with 127) have since shown that hypothermia reduces both the frequency and severity of lesions observed on MRI but none of these trials included prognostic measures derived from proton MRS. The prognostic accuracy of conventional MRI was variable and suboptimal in these studies (sensitivities 60-90% and specificities 65-92%) despite a single expert reporting the scans. In routine clinical practice, where scans are often reported by general paediatric or adult neuroradiologists, the accuracy is likely to be even lower.
Of the 190 infants assessed at 2 years after their initial injury, only 31 (16%) had adverse neurodevelopment, which is a lower proportion than we had anticipated when designing the study. This result might reflect im provements attributed to the implementation and rapid initiation of therapeutic hypothermia, and the increased tendency to cool infants with mild ence phalopathy. 22 Many tertiary centres in the UK and other highincome coun tries now routinely cool infants with mild neonatal 
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en cephalopathy. 22 However, there is little evidence to support such a practice, 23 and cooling in mild neonatal en cephalopathy should not be considered standard care until further animal study and clinical data are available.
Trials examining the optimal duration and delayed initiation of hypothermia in moderate and severe neonatal encephalopathy have also reported lower adverse event rates than expected. 24, 25 The lower frequency of adverse outcomes would require much larger sample sizes for trials based on neuro developmental outcome measures, increasing the need for early accurate surrogate endpoints derived from proton MRS. Without exploiting such surrogate endpoints, early phase trials will soon become prohibitively long and expensive. When applied to a population at much higher risk of adverse outcome than in our study, the sensitivity and specificity of thalamic NAA concentration will remain unchanged and the positive predictive value (86%) might increase, whereas the negative predictive value (100%) might decrease.
There are some limitations to this study. First, we only assessed NAA concentration in a subset of the population, at five of the eight study sites. Nevertheless, this subset used clinical MR scanners from three vendors-Philips, Siemens, and GE Healthcare-thus reflecting the range of systems available in clinical practice. The clinical characteristics, brain injury, and neurodevelop men tal outcomes of infants who had thalamic NAA con centration measurements were similar to those who did not.
In this study, measurement of thalamic NAA concen tration required a long acquisition duration (approx imately 25 min) to accurately measure sources of meas urement bias due to pathology (ie, individual metabolite and water T 1 and T 2 values). This will not be necessary in future studies, and the acquisition time for NAA concentration can be shortened dramatically (by a factor of at least two), still using clinically available vendorprovided pulse sequences, and without the need for additional research authorisations with any of the three vendors considered (Philips, Siemens, and GE Healthcare). This simple and rapid acquisition proto col has been effectively applied in the HELIX trial (NCT02387385)-which has recruited 408 infants with moderate or severe neonatal encephalo pathy from eight different centres in India, Sri Lanka, and Bangladesh and involves clinical scanners from all three vendors-with highquality proton MRS data obtained throughout. 26 A second limitation is the large number of participants we excluded prior to DWMRI analysis. In the absence of a phantom with a well defined ground truth (ie, gold standard) for validating DWMRI measures in the study, we restricted the analysis to two sites that recruited a large proportion of participants and shared equivalent MR gradient coils and operating software versions. This minimised the likelihood of introducing intersite vari ance due to acquisition protocol alone. There remains considerable interest in the analysis of DWMRI data for multicentre multivendor studies in various patient populations, and progress has been made in this area since the initiation of this study. 27 However, this limitation to our study highlights the difficulty in applying DWMRI to multicentre studies compared with proton MRS, where more sites can be included.
A third limitation is related to the interpretation of surrogate biomarkers. Although these data show the clear prognostic potential of cerebral MR biomarkers in cooled infants, it is not clear whether a proposed intervention would affect these values, and if so, whether a change in these biomarkers influences an individual's outcome.
The only way to test this is through phase 3 interventional trials with the biomarkers alongside the gold standard of careful assessment of neurodevelopmental outcome, and several such multi centre trials are currently in progress. 26, 28 We chose to focus on the thalamus for proton MRS, which could theoretically miss injury specific to other brain regions. The thalamus has exceptionally high metabolic activity in the neonatal brain, and so is dis proportionately affected by acute injury. 29 Furthermore, the clinical impact of thalamic injury is often apparent by 2 years of age. The high prognostic accuracy of NAA concentration in our study, independent of the pattern of visible cerebral injury, supports this notion.
The data from this study have several key implications for research and clinical practice. Typically, neonatal neuroprotection trials are powered for a primary outcome derived from clinical assessments years after the intervention. As a result, such trials require large numbers of participants, and so the smallest earlyphase studies will still have a duration of several years. 25, 30 The mea surement of NAA concentration could therefore improve the efficiency of neonatal neuroprotective trials in one of two ways. One option is for it to be adopted as a surrogate outcome measure in a phase 2 study to give a rapid goor nogo assessment. Such a model was adopted by Azzopardi and colleagues 31 who did not find any effect of the intervention (Xenon gas) on DWMRI or lactate-NAA peakarea ratio from MRS. Unlike the latter measure, NAA concentration is normally distributed and more clearly separates between normal and adverse outcomes, while explaining more of the variation in 2year outcome measures across participants. Further more, the MR protocol used in the TOBY Xenon trial 13 was limited to a small number of 3·0 Tesla scanners from a single vendor (Philips) with closely matched hardware and software specifications, limiting general isability.
Alternatively, NAA concentration could be used to opti mise protocol design before proceeding to a phase 3 trial. For example, several putative adjuvant therapies require careful doseescalation studies to maximise the likeli hood of neuroprotective effects and define an optimal dos ing range. One such ongoing multicentre trial (COMET, NCT03409770) is examining thalamic NAA con centra tion in infants with mild encephalopathy randomly assigned to different cooling durations, so as to model the dura tion response curve and determine an optimal treatment duration.
Finally, the standardisation and application of harmon ised proton MRS protocols across scanners from multiple vendors and across different sites overcomes a key roadblock in the routine clinical use of MRS in neonatal encephalopathy, by providing normal ranges and cutoff values for adverse outcomes. The standardised acquisition and analysis protocols for this study are given in the MR technical summary (appendix). Given that the proton MRS techniques employed in this study are widely available on clinical scanners, they can be added to existing clinical protocols to improve routine prognostication or incorporated into clinical trial protocols to provide surrogate outcome measures.
In conclusion, proton MRS biomarkers acquired soon after birth, particularly thalamic NAA concentration, can accurately predict neurodevelopment 2 years after neo natal encephalopathy. Thus, we believe that all infants with neonatal encephalopathy should receive proton MRS as part of their routine care. Additionally, it can be applied to increase the power of neuroprotection trials while reducing their duration.
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